Search

Search Constraints

You searched for: Author/Creator Qiu, Lugui

Search Results

1. 1q21 gain but not t(4;14) indicates inferior outcomes in multiple myeloma treated with bortezomib. Issue 5 (15th April 2020)

2. A multicenter, open‐label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma. Issue 11 (29th September 2014)

3. A Phase1b Dose Escalation Study of Recombinant Circularly Permuted TRAIL in Patients With Relapsed or Refractory Multiple Myeloma. (October 2018)

4. A pivotal role of bone remodeling in granulocyte colony stimulating factor induced hematopoietic stem/progenitor cells mobilization1. Issue 5 (28th January 2013)

5. A pivotal role of bone remodeling in granulocyte colony stimulating factor induced hematopoietic stem/progenitor cells mobilization1. Issue 5 (28th January 2013)

6. A two‐part, single‐arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed/refractory B‐cell malignancies. (5th April 2022)

7. BCL-2 and MYC gain/amplification is correlated with central nervous system involvement in diffuse large B cell lymphoma at leukemic phase. Issue 1 (December 2017)

8. Benefit of rituximab maintenance is associated with Follicular Lymphoma International Prognostic Index in patients with follicular lymphoma. Issue 2 (9th December 2022)

9. Continuous treatment with lenalidomide and low‐dose dexamethasone in transplant‐ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial. (20th January 2017)

10. Downregulated miR-33b is a novel predictor associated with disease progression and poor prognosis in multiple myeloma. Issue 7 (July 2015)